Masuda Mari

マスダマリ | Masuda Mari

Affiliation and department：

Research field (1)： Medical biochemistry

Research keywords (5)： Reverse-phase Protein Array (RPPA) , 分子標的治療薬 , バイオマーカー , トランスレーショナルリサーチ , プロテオミクス

Research theme for competitive and other funds (14)：

2023 - 2025 線維化腫瘍に対する複合がん免疫療法の効果予測バイオマーカー確立
2023 - 2024 Establishment of a Reverse Phase Protein Array Platform for Diagnosis of Cancer High-Risk Groups Based on Genomic Instability.
2020 - 2023 Development of a diagnostic platform for precision oncology by applying reverse-phase phosphoprotein array to an analysis of formalin-fixed paraffin-embedded (FFPE) tissue
2022 - 2023 Establishment of a Reverse Phase Protein Array Platform for Diagnosis of Cancer High-Risk Groups Based on Genomic Instability.
2020 - 骨肉腫患者に新たな治療選択肢を;TNIK阻害剤による骨肉腫分化転換誘導を介した新規治療薬の開発

Show all

Papers (51)：

Yoshiaki Maru, Mami Kohno, Kiyomi Suzuka, Akiko Odaka, Mari Masuda, Akinobu Araki, Makiko Itami, Naotake Tanaka, Yoshitaka Hippo. Establishment and characterization of multiple patient-derived organoids from a case of advanced endometrial cancer. Human cell. 2024
Mari Masuda, Riko Nakagawa, Tadashi Kondo. Harnessing the potential of reverse-phase protein array technology: Advancing precision oncology strategies. Cancer science. 2024
Takahiko Akiyama, Tadahito Yasuda, Tomoyuki Uchihara, Noriko Yasuda-Yoshihara, Benjy J Y Tan, Atsuko Yonemura, Takashi Semba, Juntaro Yamasaki, Yoshihiro Komohara, Koji Ohnishi, et al. Stromal Reprogramming through Dual PDGFRα/β Blockade Boosts the Efficacy of Anti-PD-1 Immunotherapy in Fibrotic Tumors. Cancer research. 2023. 83. 5. 753-770
Masuda Mari. Potential utility of reverse-phase protein array for refining precision cancer medicine. Electrophoresis Letters. 2022. 66. 1. 31-34
Hidetaka Suzuki, Shuichi Mitsunaga, Masafumi Ikeda, Takao Aoyama, Kazumi Yoshizawa, Hiroki Yoshimatsu, Norisuke Kawai, Mari Masuda, Tomofumi Miura, Atsushi Ochiai. Clinical and Tumor Characteristics of Patients with High Serum Levels of Growth Differentiation Factor 15 in Advanced Pancreatic Cancer. Cancers. 2021. 13. 19

ｍore...

MISC (91)：

Aoyama T, NIshijima N, Goto N, Matsuno y, Yoshioka K, Seike M, Masuda M. Targeting the Nuclear FGF2-FGFR1 Autocrine Signaling Pathway: A Promising Therapeutic Approach for Malignant Pleural Mesothelioma. 2023
Shuichi Mitsunaga, Mari Masuda, Hiroki Yoshimatsu, Yoichi Kamei, Mitsuhito Sasaki, Kazuo Watanabe, Masafumi Ikeda. Abstract 2238: RAS activity-related features of metastatic pancreatic cancer. Cancer Reserach Volume 83, Issue 7_Supplement. 2023. 83. 7_Supplement
Aoyama, Takeda S, Goto N, Matsuno Y, Yoshioka K, Seike M, Masuda M. Potential Therapeutic Option Targeting Nuclear FGF2-FGFR1 Autocrine Signaling Pathway in Malignant Pleural Mesothelioma. 日本癌学会学術総会抄録集(Web). 2023. 82nd
Takeda S, Shiokawa D, Aoyama T, Yoshioka K, Okamoto K, Masuda M. Reverse-Phase Protein Array for Proteo-Epigenomic Profiling of Colorectal Cancer Patient-Derived Organoids. 日本癌学会学術総会抄録集(Web). 2023. 82nd
鈴木秀隆, 光永修一, 増田万里, 池田公史, 吉松宏樹, 亀井陽一. 血清Growth differentiation factor 15濃度高値の進行膵がん患者の特徴(The characteristics of patients with high serum levels of growth differentiation factor 15 in advanced pancreatic cancer). 日本癌学会総会記事. 2022. 81回. P-3221

ｍore...

Professional career (2)：

Committee career (4)：

Association Membership(s) (4)：

日本患者由来がんモデル学会 , 日本臨床プロテオゲノミクス学会 , Global Reverse-Phase Protein Array Society , Japan Cancer Association

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page